Per Stirling Capital Management LLC. Boosts Stock Position in Merck & Co., Inc. (NYSE:MRK)

Per Stirling Capital Management LLC. raised its stake in Merck & Co., Inc. (NYSE:MRKFree Report) by 2.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,691 shares of the company’s stock after purchasing an additional 85 shares during the period. Per Stirling Capital Management LLC.’s holdings in Merck & Co., Inc. were worth $402,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently added to or reduced their stakes in MRK. WealthPlan Investment Management LLC boosted its position in Merck & Co., Inc. by 3,477.6% in the third quarter. WealthPlan Investment Management LLC now owns 10,232 shares of the company’s stock valued at $1,053,000 after buying an additional 9,946 shares during the last quarter. Landscape Capital Management L.L.C. acquired a new position in Merck & Co., Inc. in the third quarter valued at approximately $669,000. Soltis Investment Advisors LLC lifted its holdings in Merck & Co., Inc. by 5.8% in the third quarter. Soltis Investment Advisors LLC now owns 15,615 shares of the company’s stock valued at $1,608,000 after acquiring an additional 860 shares during the period. Sequoia Financial Advisors LLC lifted its holdings in Merck & Co., Inc. by 2.2% in the third quarter. Sequoia Financial Advisors LLC now owns 58,254 shares of the company’s stock valued at $6,005,000 after acquiring an additional 1,239 shares during the period. Finally, ProVise Management Group LLC lifted its holdings in Merck & Co., Inc. by 6.2% in the third quarter. ProVise Management Group LLC now owns 13,315 shares of the company’s stock valued at $1,371,000 after acquiring an additional 778 shares during the period. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on MRK. Wells Fargo & Company boosted their price target on Merck & Co., Inc. from $130.00 to $135.00 and gave the company an “equal weight” rating in a report on Wednesday, March 27th. TheStreet downgraded Merck & Co., Inc. from a “b+” rating to a “c+” rating in a report on Monday, March 4th. Cantor Fitzgerald reissued an “overweight” rating and issued a $155.00 price target on shares of Merck & Co., Inc. in a report on Tuesday. Berenberg Bank boosted their price target on Merck & Co., Inc. from $140.00 to $143.00 and gave the company a “buy” rating in a report on Monday, April 8th. Finally, Truist Financial boosted their price target on Merck & Co., Inc. from $142.00 to $143.00 and gave the company a “buy” rating in a report on Friday, April 26th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $133.00.

Read Our Latest Analysis on MRK

Merck & Co., Inc. Price Performance

Shares of MRK traded up $0.73 during trading hours on Wednesday, hitting $129.44. 5,009,433 shares of the stock were exchanged, compared to its average volume of 8,103,171. The company has a debt-to-equity ratio of 0.77, a quick ratio of 0.99 and a current ratio of 1.25. Merck & Co., Inc. has a 12-month low of $99.14 and a 12-month high of $133.10. The company has a market cap of $327.85 billion, a price-to-earnings ratio of 143.91, a price-to-earnings-growth ratio of 1.65 and a beta of 0.39. The stock’s 50-day moving average price is $128.61 and its two-hundred day moving average price is $121.02.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last issued its quarterly earnings results on Thursday, April 25th. The company reported $2.07 EPS for the quarter, topping the consensus estimate of $1.94 by $0.13. The firm had revenue of $15.78 billion during the quarter, compared to analysts’ expectations of $15.21 billion. Merck & Co., Inc. had a return on equity of 14.05% and a net margin of 3.76%. The firm’s revenue for the quarter was up 8.9% on a year-over-year basis. During the same period in the previous year, the business earned $1.40 earnings per share. Research analysts expect that Merck & Co., Inc. will post 8.64 earnings per share for the current year.

Merck & Co., Inc. Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, July 8th. Stockholders of record on Monday, June 17th will be issued a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a dividend yield of 2.38%. The ex-dividend date is Monday, June 17th. Merck & Co., Inc.’s dividend payout ratio is presently 342.22%.

Merck & Co., Inc. Company Profile

(Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

Read More

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKFree Report).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.